Page last updated: 2024-08-05 12:16:32
organic heterooctacyclic compound
null
ChEBI ID: 38165
Members (6)
| Member | Definition | Role |
|---|---|---|
| kt 5720 | An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of hexyl (3S)-3-hydroxy-2-methyltetrahydrofuran-3-carboxylate (the 2R,3S,5S product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1,5-dihydro-2H-pyrrol-2-one. | KT 5720 |
| kt 5823 | An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of methyl (3R)-3-methoxy-2-methyltetrahydrofuran-3-carboxylate (the 2S,3R,5R product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1-methyl-1,5-dihydro-2H-pyrrol-2-one. | KT 5823 |
| kt 5926 | An organic heterooctacyclic compound that is 5-propoxy-1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of methyl (3R)-3-hydroxy-2-methyltetrahydrofuran-3-carboxylate (the 2S,3R,5R product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1,5-dihydro-2H-pyrrol-2-one. | KT 5926 |
| midostaurin | An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine. | midostaurin |
| sf 2370 | A organic heterooctacyclic compound that is a potent inhibitor of protein kinase C and is isolated from Nocardiopsis sp K-252a | K-252a |
| staurosporine | staurosporine |
Research
Studies (1,588)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (0.25) | 18.7374 |
| 1990's | 279 (17.57) | 18.2507 |
| 2000's | 550 (34.63) | 29.6817 |
| 2010's | 561 (35.33) | 24.3611 |
| 2020's | 194 (12.22) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 37 (2.21%) | 5.53% |
| Reviews | 103 (6.16%) | 6.00% |
| Case Studies | 31 (1.85%) | 4.05% |
| Observational | 2 (0.12%) | 0.25% |
| Other | 1,499 (89.65%) | 84.16% |